Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Stephenne, Xavier ^a,b   Nicastro, Emanuele ^a,b   Eeckhoudt, Stephane ^b   Hermans, Cedric ^b   Nyabi, Omar ^a   Lombard, Catherine ^a   Najimi, Mustapha ^a   Sokal, Etienne ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD SAMPLING; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LIVER CELL; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; MONOTHERAPY; MYOFIBROBLAST; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTHROMBIN TIME; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; THROMBIN TIME;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; CHILD; FEMALE; HEPARIN; HIRUDINS; HUMANS; LIPOPROTEINS; LIVER TRANSPLANTATION; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOPLASTIN; YOUNG ADULT;

EID: 84866634823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042819     Document Type: Article

References (39)

1. Baccarani U, Adani GL, Sanna A, Avellini C, Sainz-Barriga M, et al. ((2005)) Portal vein thrombosis after intraportal hepatocytes transplantation in a liver transplant recipient. Transpl Int 18:: 750--754.
2. Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, et al. ((1998)) Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med. 338:: 1422--1426.
3. Najimi M, Sokal E, ((2005)) Liver cell transplantation. Minerva Pediatr. 57:: 243--257.
4. Sokal EM, Smets F, Bourgois A, Van Maldergem L, Buts JP, et al. ((2003)) Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique,safety, and metabolic follow-up. Transplantation 76:: 735--738.
5. Stephenne X, Najimi M, Smets F, Reding R, de Ville d G, et al. ((2005)) Cryopreserved liver cell transplantation controls ornithine transcarbamylase deficient patient while awaiting liver transplantation. Am J Transplant. 5:: 2058--2061.
6. Stephenne X, Najimi M, Sibille C, Nassogne MC, Smets F, et al. ((2006)) Sustained engraftment and tissue enzyme activity after liver cell transplantation for argininosuccinate lyase deficiency. Gastroenterology 130:: 1317--1323.
7. Fisher RA, Bu D, Thompson M, Tisnado J, Prasad U, et al. ((2000)) Defining hepatocellular chimerism in a liver failure patient bridged with hepatocyte infusion. Transplantation 69:: 303--307.
8. Stéphenne X, Vosters O, Najimi M, Beuneu C, Dung KN, et al. ((2007)) Tissue factor-dependent procoagulant activity of isolated human hepatocytes: relevance to liver cell transplantation. Liver Transpl. 13(4):: 599--606.
9. Gustafson EK, Elgue G, Hughes RD, Mitry R, Sanchez J, et al. ((2011)) The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation. Transplantation. 91(6):: 632--638.
10. Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O, ((2000)) Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci (105) pp. 125--133.
11. Beuneu C, Vosters O, Movahedi B, Remmelink M, Salmon I, et al. ((2004)) Human pancreatic duct cells exert tissue factor-dependent procoagulant activity: relevance to islet transplantation. Diabetes 53:: 1407--1411.
12. Johansson H, Lukinius A, Moberg L, Lundgren T, Berne C, et al. ((2005)) Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 54:: 1755--1762.
13. Moberg L, Johansson H, Lukinius A, Berne C, Foss A, et al. ((2002)) Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 360:: 2039--2045.
14. Najimi M, Khuu DN, Lysy PA, Jazouli N, Abarca J, et al. ((2007)) Human Adult liver-derived mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant. 16:: 717--728.
15. Furlani D, Ugurlucan M, Ong L, Bieback K, Pittermann E, et al. ((2009)) Is the intravascular administration of mesenchymal stem cells safe? Mesenchymal stem cells and intravital microscopy. Microvasc Res. 77:: 370--376.
16. Lysy PA, Campard D, Smets F, Najimi M, Sokal EM, ((2008)) Stem cells for liver tissue repair: current knowledge and perspectives. World J Gastroenterol. 14:: 864--875.
17. Khuu DN, Scheers I, Ehnert S, Jazouli N, Nyabi O, et al. ((2011)) In vitro differentiated adult human liver progenitor cells display mature hepatic metabolic functions: a potential tool for in vitro pharmacotoxicological testing. Cell Transplant. 20:: 287--302.
18. Bajaj MS, Steer S, Kuppuswamy MN, Kisiel W, Bajaj SP, ((1999)) Synthesis and expression of tissue factor pathway inhibitor by serum-stimulated fibroblasts, vascular smooth muscle cells and cardiac myocytes. Thromb Haemost. 82:: 1663--1672.
19. Xuereb JM, Herbert JM, Sie P, Boneu B, Constans J, ((1999)) Effects of heparin and related sulfated polysaccharides on tissue factor expression induced by mitogenic and non-mitogenic factors in human vascular smooth muscle cells. Thromb Haemost. 81:: 151--156.
20. Alban S, Gastpar R, ((2001)) Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins Thromb Haemost. 85(5):: 824--829.
21. Garg HG, Thompson BT, Hales CA, ((2000)) Structural determinants of antiproliferative activity of heparin on pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 279:: 779--789.
22. Mrabat H, Garg HG, Hales CA, ((2009)) Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment. J Cell Physiol. 221:: 603--608.
23. Wang J, Rabenstein DL, ((2009)) Interaction of heparin and heparin-derived oligosaccharides with synthetic peptide analogues of the heparin-binding domain of heparin/heparan sulfate-interacting protein. Biochim Biophys Acta. 1790:: 1689--1697.
24. Savage JM, Gilotti AC, Granzow CA, Molina F, Lowe-Krentz LJ, ((2001)) Antibodies against a putative heparin receptor slow cell proliferation and decrease MAPK activation in vascular smooth muscle cells. J Cell Physiol. 187:: 283--293.
25. Patton WA 2nd, Granzow CA, Getts LA, Thomas SC, Zotter LM, et al ((1995)) Identification of a heparin-binding protein using monoclonal antibodies that block heparin binding to porcine aortic endothelial cells. Biochem J. 15:: 461--469.
26. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J, ((1994)) Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis. 5(6):: 879--887.
27. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, et al. ((1993)) Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation. J Clin Invest 91:: 547--552.
28. Pepke W, Eisenreichn A, Jaster M, Ayral Y, Bobbert P, et al. (2011). Bivalirudin Inhibits Periprocedural Platelet Function and Tissue Factor Expression of Human Smooth Muscle Cells. Cardiovasc Ther. Epub ahead of print.
29. Biemond BJ, Levi M, Nurmohamed MT, Büller HR, ten Cate JW, ((1994)) Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model. Thromb Haemost. 72(3):: 377--80.
30. Meddahi S, Samama MM, ((2009)) Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone? Blood Coagul Fibrinolysis. 20:: 207--214.
31. Koutouzis M, Lagerqvist B, James S, Omerovic E, Matejka G, et al. ((2011)) Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Heart 97(18):: 1484--1488.
32. Forbes TJ, Hijazi ZM, Young G, Ringewald JM, Aquino PM, et al. ((2011)) Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv. 77:: 671--679.
33. Lysy PA, Campard D, Smets F, Malaise J, Mourad M, et al. ((2008)) Persistence of a chimerical phenotype after hepatocyte differentiation of human bone marrow mesenchymal stem cells. Cell Prolif. 41:: 36--58.
34. Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM, ((2007)) Human skin fibroblasts: From mesodermal to hepatocyte-like differentiation. Hepatology 46:: 1574--1585.
35. Guimarães EL, Empsen C, Geerts A, van Grunsven LA, ((2010)) Advanced glycation end products induce production of reactive oxygen species via the activation of NADPH oxidase in murine hepatic stellate cells. J Hepatol. 52(3):: 389--397.
36. Pouplard C, Reverdiau-Moalic P, Piquemal R, Watier H, Lebranchu Y, et al. ((1995)) Simplified and low-cost one-stage chromogenic assay for tissue factor dependent procoagulant activity of endothelial cells. Thromb Res. 15:: 527--534.
37. Feng L, Shen-Tu J, Liu J, Chen J, Wu L, et al. ((2009)) Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects. Clin Ther. 31:: 1559--1567.
38. Gerotziafas GT, Chakroun T, Samama MM, Elalamy I, ((2004)) In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost. 92:: 1296--1302.
39. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, et al. ((2010)) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 103(4):: 815--825.